Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory legal ruling

Appeals Court Revives Tylenol Autism Lawsuits

Analysis based on 23 articles · First reported Jul 13, 2026 · Last updated Jul 16, 2026

Sentiment
-10
Attention
4
Articles
23
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Kenvue shares fell about 1% after the ruling, reflecting renewed litigation risk. The revived lawsuits could lead to significant legal costs and reputational damage for Kenvue and retailers, though the scientific link remains unproven.

Pharmaceuticals Retail

On July 13, 2026, the United States — United States Court of Appeals for the Third Circuit reversed a lower court's dismissal of over 500 lawsuits against Kenvue, the maker of Tylenol, and retailers including CVS, Kroger, Target, Walgreens, and Walmart. The plaintiffs allege that prenatal exposure to acetaminophen (Tylenol) caused autism or ADHD in their children. The appeals court ruled that the district judge improperly excluded testimony from three expert witnesses, including Andrea Baccarelli of Harvard T.H. Chan School of Public Health, finding their methodologies acceptable. The court emphasized it was not deciding on causation. The decision revives litigation that had been dismissed in December 2024. Kenvue maintains the product is safe and plans to challenge the experts' reliability again. The case has drawn political attention after President Donald Trump and Health Secretary Robert F. Kennedy Jr. suggested a link in 2025, though scientific consensus remains divided. Kenvue was spun off from Johnson & Johnson in 2023 and agreed to be acquired by Kimberly-Clark in a $40 billion deal.

90 Kimberly-Clark acquired Kenvue
70 Denise Cote excluded testimony Andrea Baccarelli
60 Robert F. Kennedy Jr. warned against use
50 Kenvue defended safety
50 Donald Trump claimed link
50 Kenvue disputed link
50 Andrea Baccarelli published review
40 Robert F. Kennedy Jr. consulted with expert Andrea Baccarelli
30 Ashley Keller praised ruling
stock
Primary defendant; faces revived lawsuits alleging failure to warn about autism/ADHD risk. Stock fell 1% on ruling.
Importance 100.0 Sentiment -30.0
govactor
Issued ruling reviving lawsuits; found lower court improperly excluded expert testimony.
Importance 80.0 Sentiment 0.0
per
Lead expert witness for plaintiffs; dean of Harvard Chan School; his testimony was reinstated.
Importance 50.0 Sentiment 0.0
per
As president, urged pregnant women not to take Tylenol, citing unproven autism link; intensified public scrutiny.
Importance 40.0 Sentiment -10.0
govactor
HHS, under Kennedy, was involved in the political controversy; its actions are cited in the context of the debate.
Importance 30.0 Sentiment -10.0
cnt
Jurisdiction; political involvement via Trump administration; FDA and CDC mentioned.
Importance 30.0 Sentiment 0.0
stock
Acquiring Kenvue in $40B deal; litigation risk may affect acquisition terms or integration.
Importance 30.0 Sentiment -10.0
per
Health Secretary; consulted with Baccarelli and announced FDA warnings; amplified controversy.
Importance 30.0 Sentiment -10.0
per
Circuit judge who wrote the unanimous opinion reversing dismissal.
Importance 30.0 Sentiment 0.0
per
District judge who originally dismissed lawsuits; her exclusion of experts was reversed.
Importance 30.0 Sentiment 0.0
stock
Former parent of Kenvue; spun off in 2023, not directly involved but legacy exposure.
Importance 20.0 Sentiment -5.0
stock
Named as defendant for selling generic acetaminophen; faces potential liability.
Importance 20.0 Sentiment -5.0
stock
Named as defendant; similar exposure as retailer.
Importance 20.0 Sentiment -5.0
stock
Named as defendant; similar exposure.
Importance 20.0 Sentiment -5.0
stock
Named as defendant; similar exposure.
Importance 20.0 Sentiment -5.0
+ 12 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.